Our aim is to accelerate the development of new treatments and diagnostics through targeted investment to improve the standard of care and deliver meaningful value to the millions of people living with lupus worldwide. Lupus Ventures was founded by the Lupus Research Alliance in 2026. The Lupus Research Alliance is the world’s largest private funder of lupus research.
About Us
Lupus Ventures (dba “The Lupus Ventures Fund”) is the world’s only venture capital fund dedicated to systemic lupus erythematosus (SLE), its manifestations, and related autoimmune conditions.
Read the Full LetterWith our depth of expertise and knowledge in this area, Lupus Ventures is uniquely positioned to support companies developing potential therapies and diagnostics to benefit people living with lupus globally.
Nishant Rastogi Managing Director
About Lupus
Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. In lupus, the immune system, meant to defend against infections, produces autoantibodies that mistake the body’s own cells as foreign, causing other immune cells to attack organs such as the kidneys, brain, heart, lungs, and skin, as well as blood and joints. Ninety percent of people with lupus are women, most often diagnosed between the ages of 15-45. Black, Latinx, Indigenous, Asian and Pacific Islander people are disproportionately affected.
Our Partnership
Lupus Ventures is the venture investment fund of the Lupus Research Alliance, the world’s largest private funder of lupus research. Our affiliation with the Lupus Research Alliance enables Lupus Ventures to be a ‘value-added’ investor, providing more than just financial capital to its portfolio companies. Companies that receive an investment from Lupus Ventures will benefit from the breadth and depth that spans bench to bedside. The clinical affiliate of the LRA, Lupus Therapeutics, is involved in 25–30% of active lupus trials.
May 19, 2026